BioCryst Pharmaceuticals (BMV:BCRX *) - Aandelenkoers, Nieuws & Analyse

BCRX * Overzicht aandelen

BioCryst Pharmaceuticals, Inc. is een biotechnologiebedrijf dat orale therapeutica op basis van kleine moleculen en eiwitten ontwikkelt voor de behandeling van zeldzame ziekten.

Over het bedrijf

BCRX * fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

Verhandeld tegen 80.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 70.45% per jaar groeien

Risicoanalyse

Negatief eigen vermogen

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar verwaterd

BioCryst Pharmaceuticals, Inc. Concurrenten

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.1b

Bicycle Therapeutics

NasdaqGS:BCYC

US$1.6b

Nurix Therapeutics

NasdaqGM:NRIX

US$1.7b

MannKind

NasdaqGM:MNKD

US$1.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor BioCryst Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$170.00
52 Week Hoogtepunt	US$170.00
52 Week Laag	US$98.29
Bèta	1.88
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-45.11%
5 jaar verandering	n/a
Verandering sinds IPO	149.82%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BCRX *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe BCRX * presteerde ten opzichte van de MX Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe BCRX * presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is BCRX *'s price volatile compared to industry and market?
BCRX * volatility
BCRX * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: De aandelenkoers van BCRX * is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van BCRX * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1986	536	Jon Stonehouse	www.biocryst.com

BioCryst Pharmaceuticals, Inc., een biotechnologiebedrijf, ontwikkelt orale therapeutica op basis van kleine moleculen en eiwitten voor de behandeling van zeldzame ziekten. Het bedrijf brengt peramivir injectie op de markt, een intraveneuze neuraminidaseremmer voor de behandeling van acute ongecompliceerde griep onder de namen RAPIVAB, RAPIACTA en PERAMIFLU; en ORLADEYO, een orale serineproteaseremmer voor de behandeling van erfelijk angio-oedeem. Het ontwikkelt ook BCX10013, een orale factor D-remmer voor complementgemedieerde ziekten.

BioCryst Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van BioCryst Pharmaceuticals zich tot de beurswaarde?
BCRX * fundamentele statistieken
Marktkapitalisatie	Mex$34.92b
Inkomsten(TTM)	-Mex$2.94b
Inkomsten(TTM)	Mex$7.71b

4.5x

P/S-verhouding

-11.9x

Koers/Winstverhouding

Is BCRX * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BCRX * resultatenrekening (TTM)
Inkomsten	US$382.24m
Kosten van inkomsten	US$202.37m
Brutowinst	US$179.86m
Overige uitgaven	US$325.80m
Inkomsten	-US$145.93m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 04, 2024

Winst per aandeel (EPS)	-0.71
Brutomarge	47.06%
Nettowinstmarge	-38.18%
Schuld/Eigen Vermogen Verhouding	-176.1%

Hoe presteerde BCRX * op de lange termijn?

Bekijk historische prestaties en vergelijking

BCRX * Overzicht aandelen

Beloningen

Risicoanalyse

BioCryst Pharmaceuticals, Inc. Concurrenten

BMV:LAB B

Mex$24.1b

NasdaqGS:BCYC

US$1.6b

NasdaqGM:NRIX

US$1.7b

NasdaqGM:MNKD

US$1.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Recent updates

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022)

Forecast to breakeven in 2026

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Forecast to breakeven in 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022)

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

High number of new directors

BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health

High number of new directors

Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia

BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021)

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic